Kimberly-Clark Corporation (NASDAQ: KMB) is one of the stocks Jim Cramer recently commented on. Cramer highlighted the ...

Dr. AJ Sumell, economics professor at Youngstown State University, said it's still to be determined just how many jobs other ...

In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Shares in consumer health group Kimberly-Clark ($KMB) dropped again today as a leading analyst downgraded the stock after its ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

U.S. futures followed global markets higher ahead of another big week of corporate earnings reports but an absence of economic data as the U.S. government shutdown entered its second month ...

Bullish option flow detected in Kimberly Clark with 19,717 calls trading, 19x expected, and implied vol increasing almost 2 points to 26.35%.

We recently published 11 Latest Stocks Jim Cramer Talked About. Kenvue Inc. (NYSE:KVUE) is one of the stocks Jim Cramer ...

We recently published 11 Latest Stocks Jim Cramer Talked About. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer ...